Table 2. Early and late outcomes – random effects models.
| Outcome |
Proportion/incidence rate % (95% CI) |
I2 % (X2 p-value) |
N. of studies |
|---|---|---|---|
| Early outcomes | |||
| Bleeding | 12 (8-17) | 83 (<0.01) | 17 |
| Acute kidney injury | 15 (9-24) | 89 (<0.01) | 11 |
| Renal replacement therapy | 7 (3-15) | 63 (0.01) | 7 |
| Pacemaker implantation | 10 (6-16) | 75 (<0.01) | 13 |
| Respiratory complication | 15 (12-20) | 0 (0.56) | 7 |
| Stroke | 2 (1-4) | 74 (<0.01) | 9 |
| Wound infection | 3 (2-6) | 81 (<0.01) | 10 |
| Late outcomes | |||
| Late mortality* | 6 (4-9) | 96 (<0.01) | 23 |
| Reintervention* | 2 (1-3) | 64 (<0.01) | 15 |
| Structural valve deterioration* | 3 (1-6) | 82 (<0.01) | 9 |
| Valve thrombosis* | 1 (0-2) | 49 (0.07) | 8 |
| Recurrence of TR ≥2* | 5 (2-13) | 85 (<0.01) | 4 |
| Bioprostheses | |||
| Late mortality* | 6 (2-13) | 97 (<0.01) | 8 |
| Reintervention* | 1 (1-3) | 77 (<0.01) | 5 |
| Structural valve deterioration* | 3 (1-9) | 91 (<0.01) | 4 |
| Valve thrombosis* | 0 (0-1) | 68 (0.04) | 3 |
| Recurrence of TR ≥2* | 8 (5-13) | 33 (0.22) | 3 |
| *per 100 person-years. CI: confidence interval; TR: tricuspid regurgitation | |||